Public health considerations for the introduction of new rotavirus vaccines for infants: A case study of tetravalent rhesus rotavirus-based reassortant vaccine

Epidemiologic Reviews

Volumn 21, Issue 1, 1999, Pages 24-42

  Clemens, John ^a,b   Keckich, Neysa ^b   Naficy, Abdollah ^b   Glass, Roger ^c   Rao, Malla ^b  

^a International Vaccine Institute   (South Korea)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE;

DIARRHEA; HUMAN; IMMUNIZATION; INFECTION PREVENTION; PRIORITY JOURNAL; REVIEW; ROTAVIRUS; VIRUS INFECTION;

EID: 0032824156     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.epirev.a017986     Document Type: Review

References (116)

1. Bishop RF, Davidson GD, Holmes IH, et al. Virus particles in epithelial cells of duodenal mucosa from children with acute non-bacterial gastroenteritis. Lancet 1973;2:1281-3.
2. Bern C, Glass R. Impact of diarrheal disease worldwide. In: Kapikian AZ, ed. Viral infections of the gastrointestinal tract. 2nd ed. New York, NY: Marcel Dekkei, 1994:1-26.
3. Ho MS, Glass RI, Pinsky PF, et al. Rotavirus as a cause of diarrheal morbidity and mortality in the United States. J Infect Dis 1988;158:1112-16.
4. Kapikian AZ, Hoshino Y, Chanock RM, et al. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J Infect Dis 1996;174(Suppl 1):S65-72.
5. Glass RI, Bresee JS, Parashar UD, et al. First rotavirus vaccine licensed: is there really a need? Acta Paediatr Suppl 1999;88:2-8.
6. Recommended childhood immunization schedule - United States, 1999. MMWR Morb Mortal Wkly Rep 1999;48: 12-16
7. Offit PA, Clark HF, Kapikian AZ. Vaccines against rotavirus. In: Levine MM, Woodrow GC, Kaper JB, et al., eds. New generation vaccines. 2nd ed. New York, NY: Marcel Dekker, 1997:659-71.
8. Reoviridae. In: Francki RIB, Fauquet C, Knudson D, et al., eds. Classification and nomenclature of viruses: fifth report of the International Committee on Taxonomy of Viruses. New York, NY: Springer-Verlag, 1991.
9. Flewett TH. Diagnosis of enteritis virus. Proc R Soc Med 1976;69:693-6.
10. Estes MK. Rotaviruses and their replication. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. 3rd ed. New York, NY: Raven Press, 1996:1625-55.
11. Bridger JC. Non-group A rotaviruses. In: Kapikian AZ, ed. Viral infections of the gastrointestinal tract. 2nd ed. New York, NY: Marcel Dekker, 1994:369-401.
12. Hoshino Y, Sereno MM, Midthun K, et al. Independent segregation of two antigenic specificities (VP3 and VP7) involved in neutralization of rotavirus infectivity. Proc Natl Acad Sci USA 1985;82:8701-4.
13. Offit PA, Blavat G. Identification of the two rotavirus genes determining neutralization specificities. J Virol 1986;57: 376-8.
14. Gentsch JR, Woods PA, Ramachandran M, et al. Review of G and P typing results from a global collection of rotavirus strains: implications for vaccine development. J Infect Dis 1996:174(Suppl 1):S30-6.
15. Morris CA, Flewett TH, Bryden AS, et al. Epidemic viral enteritis in a long-stay children's ward. Lancet 1975;1:4-5.
16. Kapikian AZ, Wyatt RG, Levine MM, et al. Studies in volunteers with human rotaviruses. Dev Biol Stand 1983;53: 209-18.
17. Tufvesson B, Johnsson T, Persson B. Family infections by reo-like virus: comparison of antibody titres by complement fixation and immunoelectroosmophoresis. Scand J Infect Dis 1977;9:257-61.
18. Hopkins RS, Gaspard GB, Williams FP Jr, et al. A community waterborne gastroenteritis outbreak: evidence for rotavirus as the agent. Am J Public Health 1984;74:263-5.
19. Kapikian AZ, Chanock RM. Viral gastroenteritis. In: Evans AS, ed. Viral infections of humans: epidemiology and control. 3rd ed. New York, NY: Plenum, 1989:293-340.
20. Blacklow NR, Echeverria P, Smith DH. Serological studies with reovirus-like enteritis agent. Infect Immun 1976;13: 1563-6.
21. Foster SO, Palmer EL, Gary GW Jr, et al. Gastroenteritis due to rotavirus in an isolated Pacific island group: an epidemic of 3,439 cases. J Infect Dis 1980;141:32-9.
22. Nakagomi O, Nakagomi T. Genetic diversity and similarity among mammalian rotaviruses in relation to interspecies transmission of rotavirus. Arch Virol 1991;120:43-55.
23. Yolken RH, Wyatt RG, Zissis G, et al. Epidemiology of human rotavirus types 1 and 2 as studied by enzyme-linked immunosorbent assay. N Engl J Med 1978;299:1156-61.
24. Biritwum RB, Isomura S, Yamaguchi H, et al. Seroepidemiological study of rotavirus infection in rural Ghana. Ann Trop Paediatr 1984;4:237-40.
25. Brandt CD, Kim HW, Yolken RH, et al. Comparative epidemiology of two rotavirus serotypes and other viral agents associated with pediatric gastroenteritis. Am J Epidemiol 1979;110:243-54.
26. Konno T, Suzuki H, Imai A, et al. A long-term survey of rotavirus infection in Japanese children with acute gastroenteritis. J Infect Dis 1978;138:569-76.
27. Rodriguez WJ, Kim HW, Brandt CD, et al. Longitudinal study of rotavirus infection and gastroenteritis in families served by a pediatric medical practice: clinical and epidemiologic observations. Pediatr Infect Dis J 1987;6:170-6.
28. Gurwith M, Wenman W, Hinde D, et al. A prospective study of rotavirus infection in infants and young children. J Infect Dis 1981;144:218-24.
29. Davidson GP, Bishop RF, Townley RR, et al. Importance of a new virus in acute sporadic enteritis in children. Lancet 1975;1:242-6.
30. Davidson GP, Gall DG, Petric M, et al. Human rotavirus enteritis induced in conventional piglets: intestinal structure and transport. J Clin Invest 1977;60:1402-9.
31. Holmes IH, Ruck BJ, Bishop RF, et al. Infantile enteritis viruses: morphogenesis and morphology. J Virol 1975; 16:937-43.
32. Investing in health research and development: report of the ad hoc committee on health research relating to future intervention options. Geneva, Switzerland: World Health Organization, 1996:19-33.
33. Bernstein DI, Sander DS, Smith VE, et al. Protection from rotavirus reinfection: 2-year prospective study. J Infect Dis 1991;164:277-83.
34. Ward RL, Bernstein DI. Protection against rotavirus disease after natural rotavirus infection. US Rotavirus Vaccine Efficacy Group. J Infect Dis 1994;169:900-4.
35. Matson DO, O'Ryan ML, Herrera I. Fecal antibody responses to symptomatic and asymptomatic rotavirus infections. J Infect Dis 1993;167:577-83.
36. Coulson BS, Grimwood K, Hudson IL, et al. Role of coproantibody in clinical protection of children during reinfection with rotavirus. J Clin Microbiol 1992;30:1678-84.
37. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996;335:1022-8.
38. Langer WL. Immunization against smallpox before Jenner. Sci Am 1976;234:112-17.
39. Kapikian AZ, Cline WL, Kim HW, et al. Antigenic relationships among five reovirus-like (RVL) agents by complement fixation (CF) and development of a new substitute CF antigens for the human RVL agent of infantile gastroenteritis. Proc Soc Exp Biol Med 1976;152:535-9.
40. Midthun K, Kapikian AZ. Rotavirus vaccines: an overview. Clin Microbiol Rev 1996;9:423-34.
41. Christy C, Madore HP, Treaner JJ. Safety and immunogenicity of live attenuated monkey rotavirus vaccine. J Infect Dis 1986;154:1045-8.
42. Vesikari T, Kapikian AZ, Delem A, et al. A comparative trial of rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children. J Infect Dis 1986;153:832-9.
43. Flores J, Perez-Schael I, Gonzalez M, et al. Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants. Lancet. 1987;1:882-4.
44. Santosham M, Letson GW, Wolff M, et al. A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population. J Infect Dis 1991;163:483-7.
45. Christy C, Madore HP, Pichichero ME, et al. Field trial of rhesus rotavirus vaccine in infants. Pediatr Infect Dis J 1988; 7:645-50.
46. Rennels MB, Losonsky GA, Young AE, et al. An efficacy trial of the rhesus rotavirus vaccine in Maryland. The Clinical Study Group. Am J Dis Child 1990;144:601-4.
47. Clark HF, Borian FE, Bell LM. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. J Infect Dis 1988;158: 570-87.
48. Chiba S, Yokoyama T, Nakata S, et al. Protective effect of naturally acquired homotypic and heterotypic rotavirus anti-bodies. Lancet 1986;2:417-21.
49. Vesikari T, Ruuska T, Green KY, et al. Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesus-human reassortant rotavirus vaccines with human rotavirus VP7 serotype 1 or 2 specificity. Pediatr Infect Dis J 1992; 11:535-42.
50. Madore HP, Christy C, Pichichero M, et al. Field trial of rhesus rotavirus or human-rhesus reassortant vaccine of VP7 serotype 3 or 1 specificity in infants. The Elmwood, Panorama and Westfall Pediatric Groups. J Infect Dis 1992; 166:235-43.
51. Lanata CF, Black RE, Flores J, et al. Immunogenicity, safety and protective efficacy of one dose of the rhesus rotavirus vaccine and serotype 1 and 2 human-rhesus rotavirus reassortants in children from Lima, Peru. Vaccine 1996;14: 237-43.
52. Linhares AC, Gabbay YB, Mascarenhas JD, et al. Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil. Bull World Health Organ 1996;74:491-500.
53. Bernstein DI, Glass RI, Rodgers G, et al. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group. JAMA 1995;273:1191-6.
54. Lanata CF, Midthun K, Black RE, et al. Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. J Infect Dis 1996;174:268-75.
55. Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics 1996; 97:7-13.
56. Joensuu J, Koskenniemi E, Pang XL, et al. Randomized, placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997;350:1205-9.
57. Perez-Schael I, Guntinas MJ, Perez M, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997;337: 1181-7.
58. Santosham M, Moulton LH, Reid R, et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr 1997;131: 632-8.
59. Estes MK. Advances in molecular biology: impact on rotavirus vaccine development. J Infect Dis 1996;174(Suppl 1):S37-46.
60. Cook SM, Glass RI, LeBaron C, et al. Global seasonality of rotavirus infections. Bull World Health Organ 1990;68: 171-7.
61. Clemens JD, Sack DA, Harris JR, et al. Breast feeding and the risk of severe cholera in rural Bangladeshi children. Am J Epidemiol 1990;131:400-11.
62. Ahmed F, Clemens JD, Rao MR, et al. Community-based evaluation of the effect of breast-feeding on the risk of microbiologically confirmed or clinically presumptive shigellosis in Bangladeshi children. Pediatrics 1992;90: 406-11.
63. Clemens J, Rao M, Ahmed F, et al. Breast-feeding and the risk of life-threatening rotavirus diarrhea: prevention or post-ponement? Pediatrics 1993;92:680-5.
64. Kilgore PE, Holman RC, Clarke MJ, et al. Trends of diarrheal disease-associated mortality in US children, 1968 through 1991. JAMA 1995;274:1143-8.
65. Glass RI, Lew JF, Gangarosa RE, et al. Estimates of morbidity and mortality rates for diarrheal diseases in American children. J Pediatr 1991;118:S27-33.
66. Tucker AW, Haddix AC, Bresee JS, et al. Cost-effectiveness analysis of a rotavirus vaccine program in the United States. JAMA 1998;279:1371-6.
67. Appendix D13: The prospects of immunizing against rotavirus. In: New vaccine development: establishing priorities. Vol II. Diseases of importance in developing countries. Washington, DC: National Academy Press, 1986:308-18.
68. Bern C, Martines J, de Zoysa I, et al. The magnitude of the global burden of diarrhoeal disease: a ten-year update. Bull World Health Organ 1992;70:705-14.
69. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269-76.
70. Orenstein WA, Hadler S, Kuritsky JN, et al. Rotavirus vaccines-from licensure to disease reduction. J Infect Dis 1996;174(Suppl 1):S118-24.
71. Bryden AS, Davies HA, Hadley RE, et al. Rotavirus enteritis in the West Midlands during 1974. Lancet 1975;2:241-3.
72. Kapikian AZ, Kim HW, Wyatt RG, et al. Human reoviruslike agent as the major pathogen associated with "winter" gastroenteritis in hospitalized infants and young children. N Engl J Med 1976;294:965-72.
73. Brandt CD, Kim HW, Rodriguez WJ, et al. Pediatric viral gastroenteritis during eight years of study. J Clin Microbiol 1983;18:71-8.
74. Parashar UD, Holman RC, Clarke MJ, et al. Hospitalizations associated with rotavirus diarrhea in the United States, 1993 through 1995: surveillance based on the new ICD-9-CM rotavirus-specific diagnostic code. J Infect Dis 1998;177: 13-17.
75. Urasawa S, Urasawa T, Djoko Y, et al. A survey of rotavirus infection in the tropics. Jpn J Med Sci Biol 1981;34:293-8.
76. Dagan R, Bar-David Y, Sarov B, et al. Rotavirus diarrhea in Jewish and Bedouin children in the Negev region of Israel: epidemiology, clinical aspects and possible role of malnutrition in severity of illness. Pediatr Infect Dis J 1990;9:314-21.
77. Gomwalk NE, Gosham LT, Umoh UJ. Rotavirus gastroenteritis in pediatric diarrhoea in Jos, Nigeria. J Trop Pediatr 1990;36:52-5.
78. Huilan S, Zhen LG, Mathan MM, et al. Etiology of acute diarrhoea among children in developing countries: a multicentre study in five countries. Bull World Health Organ 1991;69:549-55.
79. Patwari AK, Srinivasan A, Diwan N, et al. Rotavirus as an aetiological organism in acute watery diarrhoea in Delhi children: reappraisal of clinical and epidemiological characteristics. J Trop Pediatr 1994;40:214-18.
80. Espinoza F, Paniagua M, Hallander H, et al. Prevalence and characteristics of severe rotavirus infections in Nicaraguan children. Ann Trop Paediatr 1997;17:25-32.
81. Meqdam MM, Youssef MT, Nimri LF, et al. Viral gastroenteritis among young children in northern Jordan. J Trop Pediatr 1997;43:349-52.
82. Unicomb LE, Kilgore PE, Faruque ASG, et al. Anticipating rotavirus vaccines: hospital-based surveillance for rotavirus diarrhea and estimates of disease burden in Bangladesh. Pediatr Infect Dis J 1997;16:947-51.
83. Timenetsky M do C, Santos N, Gouvea V. Survey of rotavirus G and P types associated with human gastroenteritis in São Paulo, Brazil, from 1986 to 1992. J Clin Microbiol 1994;32:2622-4.
84. Ramachandran M, Das BK, Vij A, et al. Unusual diversity of human rotavirus G and P genotypes in India. J Clin Microbiol 1996;34:436-9.
85. Halloran ME, Haber M, Longini IM Jr, et al.. Direct and indirect effects in vaccine efficacy and effectiveness. Am J Epidemiol 1991;133:323-31.
86. Smith PG, Rodrigues LC, Fine PEM. Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. Int J Epidemiol 1984;13: 87-93.
87. Ward RL, Clemens JD, Knowlton DR, et al. Evidence that protection against rotavirus diarrhea after natural infection is not dependent on serotype-specific neutralizing antibody. J Infect Dis 1992;166:1251-7.
88. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991;13:926-39.
89. Clemens J, Brenner R, Rao M, et al. Evaluating new vaccines for developing countries: efficacy or effectiveness? JAMA 1996;275:390-7.
90. Joensuu J, Koshenniemi E, Vesikari T. Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants. Pediatr Infect Dis J 1998;17:334-40.
91. Jamison DT. Disease control priorities in developing countries: an overview. In: Jamison DT, Mosley WH, Measham AR, et al., eds. Disease control priorities in developing countries. New York, NY: Oxford University Press, 1993:3-34.
92. Bhan MK, Lew JF, Sazawal S, et al. Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. J Infect Dis 1993;168:282-7.
93. Active and passive immunization: recommended childhood immunization schedule, January-December 1997. In: Peter G, ed. 1997 Red Book: report of the Committee on Infectious Diseases. 24th ed. Elk Grove Village, IL: American Academy of Pediatrics, 1997:18-19.
94. Flores J, Daoud G, Daoud N, et al. Reactogenicity and anti-genicity of rhesus rotavirus vaccine (MMU-18006) in newborn infants in Venezuela. Pediatr Infect Dis J 1988;7:776-80.
95. Dagan R, Kassis I, Sarov B, et al. Safety and immunogenicity of oral tetravalent human-rhesus reassortant rotavirus vaccine in neonates. Pediatr Infect Dis J 1992;11:991-6.
96. Ward RL, Knowlton DR, Zito ET, et al. Serologic correlates of immunity in a tetravalent reassortant rotavirus vaccine trial. J Infect Dis 1997;176:570-7.
97. Gothefors L, Wadell G, Juto P, et al. Prolonged efficacy of rhesus rotavirus vaccine in Swedish children. US Rotavirus Vaccine Efficacy Group. J Infect Dis 1989;159:753-7.
98. Active and passive immunization: precautions and contraindications. In: Peter G, ed. 1997 Red Book: report of the Committee on Infectious Diseases. 24th ed. Elk Grove Village, IL: American Academy of Pediatrics, 1997:31-2.
99. Ventura SJ, Martin JA, Curtin SC, et al. Report of final natality statistics, 1996. Mon Vital Stat Rep 1998;46 (suppl): 1-99.
100. Rennels MB, Ward RL, Mack ME, et al. Concurrent oral poliovirus and rhesus-human reassortant rotavirus vaccination: effects on immune responses to both vaccines and on efficacy of rotavirus vaccines. The US Rotavirus Vaccine Efficacy Group. J Infect Dis 1996;173:306-13.
101. Rennels MB, Wasserman SS, Glass RI, et al. Comparison of immunogenicity and efficacy of rhesus rotavirus reassortant vaccines in breastfed and nonbreastfed children. US Rotavirus Vaccine Efficacy Group. Pediatrics 1995;96:1132-6.
102. Freidman MG, Segal B, Zedaka R, et al. Serum and salivary responses to oral tetravalent reassortant rotavirus vaccine in newborns. Clin Exp Immunol 1993;92:194-9.
103. Ceyhan M, Kanra G, Secmeer G, et al. Take of rhesus-human reassortant tetravalent rotavirus vaccine in breast-fed infants. Acta Paediatr 1993;82:223-7.
104. Fine PEM. Herd immunity: history, theory, practice. Epidemiol Rev 1993;15:265-302.
105. Halloran ME, Struchiner CJ. Study designs for dependent happenings. Epidemiology 1991;2:331-8.
106. Smith JC, Haddix AC, Teutsch SM, et al. Cost-effectiveness analysis of a rotavirus immunization program for the United States. Pediatrics 1995;96:609-15.
107. Griffiths RI. Anderson GF, Powe NR, et al. Economic impact of immunization against rotavirus gastroenteritis: evidence from a clinical trial. Arch Pediatr Adolesc Med 1995;149: 407-14.
108. Takala AK, Koskenniemi E, Joensuu J, et al. Economic evaluation of rotavirus vaccinations in Finland: randomized, double-blind, placebo-controlled trial of tetravalent rhesus rotavirus vaccine. Clin Infect Dis 1998;27:272-82.
109. de Zoysa I, Vesikari T. Cost-effectiveness of rotavirus immunization in the control of diarrhoeal diseases in developing countries. In: Sack DA, Freij L, eds. Prospects for public health benefits in developing countries from new vaccines against enteric infections: a SAREC research symposium held in Gothenburg, Sweden, May 28-29, 1990. Stockholm, Sweden: SAREC Documentation, 1990:90-101.
110. de Zoysa I, Feachem RG. Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization. Bull World Health Organ 1985;63:569-83.
111. Creese AL. Cost effectiveness of potential immunization interventions against diarrhoeal disease. Soc Sci Med 1986; 23:231-40.
112. Phillips MA, Feachem RG, Mills A. Options for diarrhoeal control: the cost and cost-effectiveness of selected interventions for the prevention of diarrhoea. London, England: Evaluation and Planning Centre for Health Care, London School of Hygiene and Tropical Medicine, 1987. (EPC publication no. 13).
113. Hinman AR, Orenstein WA. Public health considerations. In: Plotkin SA, Mortimer EA Jr, eds. Vaccines. 2nd ed. Philadelphia, PA: Saunders, 1994:903-32.
114. Vaccine Research and Development: rotavirus vaccines for developing countries. Wkly Epidemiol Rec 1997;72:35-40.
115. Keusch GT, Cash RA. A vaccine against rotavirus - when is too much too much? N Engl J Med 1997;337:1228-9.
116. Intussusception among recipients of rotavirus vaccine -United States, 1998-1999. MMWR Morb Mortal Wkly Rep 1999;48:577-81.